News from shire plc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 26, 2015, 08:00 ET

Shire and Cincinnati Children's Establish Rare Disease Research Collaboration

Shire plc (LSE: SHP, NASDAQ: SHPG) and Cincinnati Children's Hospital Medical Center today announced a three-year, broad research collaboration...

Mar 02, 2015, 07:00 ET

Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the company has submitted a New Drug Application (NDA) with the U. S. Food and Drug...

Feb 25, 2015, 09:00 ET

Shire to Present at the Cowen 35th Annual Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that Flemming Ornskov, MD, Chief Executive Officer, will present at the Cowen 35th Annual...

Feb 24, 2015, 07:00 ET

Shire Acquires Meritage Pharma

Shire plc (LSE: SHP, NASDAQ: SHPG) and Meritage Pharma, Inc. announced today that Shire has acquired Meritage, a privately-held company, for an...

Feb 23, 2015, 01:00 ET

Shire Calls for Improved Rare Disease Diagnosis on Rare Disease Day 2015

- New awareness materials posted on Shire.com highlight the challenging diagnosis journey many people with a rare disease face  -...

Feb 21, 2015, 10:26 ET

Shire Completes Acquisition of NPS Pharma

Shire plc (LSE: SHP, NASDAQ: SHPG) announces the successful completion of the tender offer for all of the outstanding shares of NPS...

Feb 12, 2015, 07:00 ET

Shire Delivers Record Revenues and Non GAAP Earnings per ADS in 2014, and Enters 2015 With Strongest-Ever Pipeline

Shire (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the year to December 31, 2014. Full Year Financial Highlights...

Feb 02, 2015, 12:46 ET

Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) Becomes First and Only Treatment Approved by the FDA for Adults with Moderate to Severe Binge Eating Disorder

 Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) approved Vyvanse® (lisdexamfetamine...

Jan 30, 2015, 18:24 ET

Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) Becomes First and Only Treatment Approved by the FDA for Adults with Moderate to Severe Binge Eating Disorder

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) approved Vyvanse® (lisdexamfetamine...

Jan 27, 2015, 17:00 ET

U.S. Supreme Court Grants Shire Petition

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the U.S. Supreme Court granted Shire's petition in the Shire v. Watson patent case...

Jan 26, 2015, 02:00 ET

Shire's Investigational SHP609, idursulfase-IT, Receives FDA Fast Track Designation for the Treatment of Neurocognitive Decline Associated with Hunter Syndrome

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the United States Food and Drug Administration (FDA) has granted Fast Track designation for...

Jan 23, 2015, 20:25 ET

Shire Comments on Press Release from NPS Pharma Regarding FDA Approval of NATPARA® (parathyroid hormone)

 Shire plc (LSE: SHP, NASDAQ: SHPG) notes the announcement today by NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) that the U.S. Food and Drug...

Jan 22, 2015, 02:05 ET

Positive Response From European Decentralised Procedure for Elvanse Adult® ▼ (lisdexamfetamine dimesylate) in Adults With ADHD

- For Release to US Media Only Shire plc (LSE: SHP, NASDAQ: SHPG) today announces the positive response from the European Decentralised Procedure...

Jan 21, 2015, 16:34 ET

Shire Added to Global 100 Sustainability Index

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it has for the first time placed in the Global 100 Sustainability Index. Shire was ranked 62nd...

Jan 11, 2015, 11:01 ET

Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech

Transaction valued at $5.2 billion Enhances growth profile Shire plc (LSE: SHP, NASDAQ: SHPG) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP)...

Jan 06, 2015, 09:00 ET

Shire to Present at 33rd Annual J.P. Morgan Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that Flemming Ornskov, MD, Chief Executive Officer, will present at the 33rd Annual J.P. Morgan...

Dec 10, 2014, 07:00 ET

Shire R&D Day Profiles Innovative Pipeline Expected to Contribute $3 Billion in Product Sales by 2020

Shire plc (LSE: SHP, NASDAQ: SHPG) is hosting a Research and Development (R&D) Day for the investment community focused on the Company's...

Dec 01, 2014, 07:30 ET

Shire to Highlight Pipeline Progress and Breadth of Innovative Portfolio in R&D Day

Company to Profile Key Late-Stage Assets Projected to Drive $3 Billion in Growth by 2020 Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that...

Nov 19, 2014, 09:25 ET

Shire to Relocate Over 500 Jobs to Massachusetts

Establishes Lexington, Mass., as U.S. Operational Headquarters; Decreases Presence in Chesterbrook, Pa.   Interim CFO Appointed  Shire...

Nov 06, 2014, 07:00 ET

Shire to Participate at the Credit Suisse 2014 Global Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it will be participating in the Credit Suisse 2014 Healthcare Conference on Wednesday, November...